IOVA Latest Press Releases

-- October 29, 2026 --

Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Globe Newswire 7:00 AM

-- October 28, 2026 --

Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy Globe Newswire 7:00 PM

-- October 27, 2026 --

Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026 Globe Newswire 7:00 AM

-- October 26, 2026 --

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market Globe Newswire 9:00 AM

Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 Globe Newswire 7:00 AM

-- October 23, 2026 --

Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced Melanoma Globe Newswire 10:15 AM

-- October 19, 2026 --

Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026 Globe Newswire 7:00 AM

-- October 16, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- October 1, 2026 --

Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer Globe Newswire 7:00 AM

-- September 29, 2026 --

High-Stakes October has these Biotechs Entering Crucial Stretch Globe Newswire 12:12 PM

Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million Globe Newswire 7:00 AM

-- September 18, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:10 PM

-- September 4, 2026 --

Iovance Biotherapeutics to Present at Upcoming Conferences Globe Newswire 8:00 AM

-- August 21, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- August 6, 2026 --

Why Investors Are Watching These Healthcare Movers Globe Newswire 12:31 PM

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates Globe Newswire 7:01 AM

-- July 30, 2026 --

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026 Globe Newswire 8:00 AM

-- July 17, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- June 19, 2026 --

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 5:15 PM

-- June 8, 2026 --

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet Globe Newswire 9:01 AM

-- June 3, 2026 --

Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes